Canlyniadau Chwilio - Patrick N. Harter

Mireinio'r Canlyniadau
  1. 1
    Fermented Mistletoe Extract as a Multimodal Antitumoral Agent in Gliomas

    Fermented Mistletoe Extract as a Multimodal Antitumoral Agent in Gliomas gan Oliver Podlech, Patrick N. Harter, Michel Mittelbronn, Simone Pöschel, Ulrike Naumann

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Adora2b Signaling on Bone Marrow Derived Cells Dampens Myocardial Ischemia-Reperfusion Injury

    Adora2b Signaling on Bone Marrow Derived Cells Dampens Myocardial Ischemia-Reperfusion Injury gan Michael Koeppen, Patrick N. Harter, Stephanie Bonney, Megan Bonney, S. Vehar, Cornelia Zachskorn, Michel Mittelbronn, Tobias Eckle

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma

    β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma gan Jenny Zinke, Fabian T. Schneider, Patrick N. Harter, Sonja Thom, Nicole Ziegler, Rune Toftgård, Karl H. Plate, Stefan Liebner

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma

    The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma gan Martha Foltyn, Anna‐Luisa Luger, Nadja I. Lorenz, Benedikt Sauer, Michel Mittelbronn, Patrick N. Harter, Jörg Steinbach, Michael Ronellenfitsch

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

    CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy gan Michael C. Burger, Congcong Zhang, Patrick N. Harter, A Romański, F Straßheimer, Christian Senft, Torsten Tonn, Joachim P. Steinbach, Winfried S. Wels

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Downstream effects of plectin mutations in epidermolysis bullosa simplex with muscular dystrophy

    Downstream effects of plectin mutations in epidermolysis bullosa simplex with muscular dystrophy gan Lilli Winter, Matthias Türk, Patrick N. Harter, Michel Mittelbronn, Cornelia Kornblum, Fiona Norwood, Heinz Jungbluth, Christian T. Thiel, Ursula Schlötzer‐Schrehardt, Rolf Schröder

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients

    MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients gan Kai Doberstein, Nico Steinmeyer, Ann‐Kathrin Hartmetz, W. Eberhardt, Michel Mittelbronn, Patrick N. Harter, Eva Juengel, Roman A. Blaheta, Josef Pfeilschifter, Paul Gutwein

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences

    Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences gan Panagiotis Balermpas, Franz Rödel, R Liberz, Julius Oppermann, Jens Wagenblast, Shahram Ghanaati, Patrick N. Harter, Michel Mittelbronn, Christian Weiß, Claus Rödel, Emmanouil Fokas

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy

    Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy gan Gabriele D. Maurer, Daniel P. Brucker, Oliver Bähr, Patrick N. Harter, Elke Hattingen, Stefan Walenta, Wolfgang Mueller‐Klieser, Joachim P. Steinbach, Johannes Rieger

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas

    Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas gan Florian Geßler, Joshua D. Bernstock, Anne K. Braczynski, Stephanie Lescher, Peter Baumgarten, Patrick N. Harter, Michel Mittelbronn, Tianxia Wu, Volker Seifert, Christian Senft

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    EGFR heterogeneity and implications for therapeutic intervention in glioblastoma

    EGFR heterogeneity and implications for therapeutic intervention in glioblastoma gan Eskil Eskilsson, Gro Vatne Røsland, Gergely Solecki, Qianghu Wang, Patrick N. Harter, Grazia Graziani, Roel G.W. Verhaak, Frank Winkler, Rolf Bjerkvig, Hrvoje Miletić

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin–dependent manner

    Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin–dependent manner gan Alexander Scholz, Victoria Lang, Reinhard Henschler, Marcus Czabanka, Peter Vajkoczy, Emmanouil Chavakis, Janina Drynski, Patrick N. Harter, Michel Mittelbronn, Daniel Dumont, Karl H. Plate, Yvonne Reiss

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma

    ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma gan Congcong Zhang, Michael C. Burger, Lukas Jennewein, Sabrina Genßler, Kurt Schönfeld, Pia S. Zeiner, Elke Hattingen, Patrick N. Harter, Michel Mittelbronn, Torsten Tonn, Jörg Steinbach, Winfried S. Wels

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine

    Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine gan Katharina J. Wenger, Marlies Wagner, Se-Jong You, Kea Franz, Patrick N. Harter, Michael C. Burger, Martin Voß, Michael Ronellenfitsch, Emmanouil Fokas, Joachim P. Steinbach, Oliver Bähr

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors

    Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors gan Dirk Walter, Patrick N. Harter, Florian Battke, Ria Winkelmann, Markus Schneider, Katharina Holzer, Christine Koch, Jörg Bojunga, Stefan Zeuzem, Martin L. Hansmann, Jan Peveling‐Oberhag, Oliver Waidmann

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    BACE-1 is expressed in the blood–brain barrier endothelium and is upregulated in a murine model of Alzheimer’s disease

    BACE-1 is expressed in the blood–brain barrier endothelium and is upregulated in a murine model of Alzheimer’s disease gan Kavi Devraj, Slobodan Poznanović, Christoph Spahn, Gerhard Schwall, Patrick N. Harter, Michel Mittelbronn, Katia Antoniello, Paolo Paganetti, Andreas Muhs, Mike Heilemann, Richard A. Hawkins, André Schrattenholz, Stefan Liebner

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial

    Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial gan Martin Voß, Katharina J. Wenger, Nina von Mettenheim, Jörg Bojunga, Manuela Vetter, Bianca Diehl, Kea Franz, Rüediger Gerlach, Michael Ronellenfitsch, Patrick N. Harter, Elke Hattingen, Joachim P. Steinbach, Claus Rödel, Johannes Rieger

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury

    The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury gan Gaby Enzmann, Caroline Mysiorek, Roser Gorina, Yu‐Jung Cheng, Sharang Ghavampour, Melanie‐Jane Hannocks, Vincent Prinz, Ulrich Dirnagl, Matthias Endres, Marco Prinz, Rudi Beschorner, Patrick N. Harter, Michel Mittelbronn, Britta Engelhardt, Lydia Sorokin

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation

    Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation gan Sylvia Torres-Odio, Jana Key, Hans-Hermann Hoepken, Júlia Canet-Pons, Lucie Valek, Bastian Roller, Michael Walter, Blas Morales-Gordo, David Meierhofer, Patrick N. Harter, Michel Mittelbronn, Irmgard Tegeder, Suzana Gispert, Georg Auburger

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis

    The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis gan Cedric Tehranian, Laura Fankhauser, Patrick N. Harter, Colin D.H. Ratcliffe, Pia S. Zeiner, Julia M. Messmer, Dirk C. Hoffmann, Katharina Frey, Dana Westphal, Michael Ronellenfitsch, Erik Sahai, Wolfgang Wick, Matthia A. Karreman, Frank Winkler

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: